source
- Sellas’ Phase 3 REGAL AML Immunotherapy Study Delayed, Forecast to Miss Survival EndpointSellas Life Sciences Group’s experimental immunotherapy galinpepimut‑S (GPS) is being tested in a Phase 3 REGAL trial for patients with acute myeloid leukemia in a second remission. The study has b…
- Lisata Therapeutics merges with Marea Therapeutics in reverse merger after failed Kuva dealLisata Therapeutics, a solid tumor biotech, announced a stock-for-stock merger with cardiovascular specialist Marea Therapeutics after a previous merger attempt with Kuva Labs collapsed. The trans…